FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2256029097> ?p ?o ?g. }

• W2256029097 endingPage "9091" @default.
• W2256029097 startingPage "9091" @default.
• W2256029097 abstract "9091 Background: Complementary and Alternative Medicine (CAM) use is common in cancer patients. This study was conducted to estimate the use of CAM in patients with advanced malignancies seen in the Department of Investigational Cancer (Phase I Program) at M. D. Anderson Cancer Center (MDACC). The objectives were to examine the prevalence of CAM use and association among its use and various covariates. Methods: Investigator-designed surveys in English, Spanish, and Arabic languages were anonymously completed and submitted by patients seen in the Phase I Program at MDACC. The unique characteristic of this study is that the surveys were written in multiple languages and filled out anonymously reducing patient fears that they would be ineligible for enrollment in Phase I clinical trials by their use of CAM. Results: A total of 276 surveys were distributed to patients and 207 (75%) surveys were returned to us and analyzed. Of these 207 unique patients, 111 (54%) used one or more CAM. Of the 111 patients, 91(82%) used pharmacologic CAM, 79 (71%) used non-pharmacologic CAM, and 60 (54%) used both modalities. The most commonly used were vitamins (n=86, 77%), prayer (n=65, 59%), and herbal products (n=30, 27%). Female patients were most likely to report their use of CAM (p<0.0009). CAM use was not associated with race, age, level of education, employment or income. Of the CAM users, 48 (43%) patients had been using CAM for >5 years. In patients under 60 years of age, 58 (51%) used CAM, whereas in patients aged 60 or older, 42 (45%) reported use of CAM. Conclusions: CAM usage is common in patients with advanced malignancies. There was no association among CAM use and race, age, education, employment, or income. However, female patients were more likely to report CAM use. It is important to assess CAM use among all patients receiving cancer treatment. Further research is warranted to better understand types of CAM used, and its risks and benefits in cancer patients. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration AstraZeneca, Centocor, Johnson & Johnson, Maxygen, Merck Amgen, AstraZeneca, Center for Biomedical Continuing Education (CBCE), Genentech, Enzon, IDSC, ImClone Systems, Johnson & Johnson, Maxygen, Merck, Pharmion, Roche Abraxis, Amgen, AmpliMed, Antigenics, AstraZeneca, Bayer, BMS, Callisto, Centocor, Concordia, Curagen, Eisai, Eli Lilly, Enzon, Exelixis, Genentech, GlaxoSmithKline, Globomax, Hoffman- La Roche, Kinex, Merck, Metastatix, MGI Pharmaceuticals, Myriad, Novartis, Pfizer, Pharmacyclics, Pharmion, Phoenix Biotech, Reata, Taiho, Vioquest, Ziopharm" @default.
• W2256029097 created "2016-06-24" @default.
• W2256029097 creator A5002835492 @default.
• W2256029097 creator A5005436649 @default.
• W2256029097 creator A5007563382 @default.
• W2256029097 creator A5012237647 @default.
• W2256029097 creator A5038774474 @default.
• W2256029097 creator A5042271475 @default.
• W2256029097 creator A5053481267 @default.
• W2256029097 creator A5064646955 @default.
• W2256029097 creator A5071506606 @default.
• W2256029097 creator A5071881182 @default.
• W2256029097 date "2010-05-20" @default.
• W2256029097 modified "2023-09-27" @default.
• W2256029097 title "The use of complementary and alternative medicine in patients seen in phase I clinical trials program." @default.
• W2256029097 doi "https://doi.org/10.1200/jco.2010.28.15_suppl.9091" @default.
• W2256029097 hasPublicationYear "2010" @default.
• W2256029097 type Work @default.
• W2256029097 sameAs 2256029097 @default.
• W2256029097 citedByCount "0" @default.
• W2256029097 crossrefType "journal-article" @default.
• W2256029097 hasAuthorship W2256029097A5002835492 @default.
• W2256029097 hasAuthorship W2256029097A5005436649 @default.
• W2256029097 hasAuthorship W2256029097A5007563382 @default.
• W2256029097 hasAuthorship W2256029097A5012237647 @default.
• W2256029097 hasAuthorship W2256029097A5038774474 @default.
• W2256029097 hasAuthorship W2256029097A5042271475 @default.
• W2256029097 hasAuthorship W2256029097A5053481267 @default.
• W2256029097 hasAuthorship W2256029097A5064646955 @default.
• W2256029097 hasAuthorship W2256029097A5071506606 @default.
• W2256029097 hasAuthorship W2256029097A5071881182 @default.
• W2256029097 hasConcept C121608353 @default.
• W2256029097 hasConcept C126322002 @default.
• W2256029097 hasConcept C138885662 @default.
• W2256029097 hasConcept C142724271 @default.
• W2256029097 hasConcept C1862650 @default.
• W2256029097 hasConcept C204787440 @default.
• W2256029097 hasConcept C41895202 @default.
• W2256029097 hasConcept C512399662 @default.
• W2256029097 hasConcept C535046627 @default.
• W2256029097 hasConcept C71924100 @default.
• W2256029097 hasConcept C96455323 @default.
• W2256029097 hasConceptScore W2256029097C121608353 @default.
• W2256029097 hasConceptScore W2256029097C126322002 @default.
• W2256029097 hasConceptScore W2256029097C138885662 @default.
• W2256029097 hasConceptScore W2256029097C142724271 @default.
• W2256029097 hasConceptScore W2256029097C1862650 @default.
• W2256029097 hasConceptScore W2256029097C204787440 @default.
• W2256029097 hasConceptScore W2256029097C41895202 @default.
• W2256029097 hasConceptScore W2256029097C512399662 @default.
• W2256029097 hasConceptScore W2256029097C535046627 @default.
• W2256029097 hasConceptScore W2256029097C71924100 @default.
• W2256029097 hasConceptScore W2256029097C96455323 @default.
• W2256029097 hasIssue "15_suppl" @default.
• W2256029097 hasLocation W22560290971 @default.
• W2256029097 hasOpenAccess W2256029097 @default.
• W2256029097 hasPrimaryLocation W22560290971 @default.
• W2256029097 hasRelatedWork W1885025562 @default.
• W2256029097 hasRelatedWork W1985812505 @default.
• W2256029097 hasRelatedWork W2108624693 @default.
• W2256029097 hasRelatedWork W2110033731 @default.
• W2256029097 hasRelatedWork W2124337430 @default.
• W2256029097 hasRelatedWork W2328471929 @default.
• W2256029097 hasRelatedWork W2411069155 @default.
• W2256029097 hasRelatedWork W2575073326 @default.
• W2256029097 hasRelatedWork W2971584765 @default.
• W2256029097 hasRelatedWork W4221063554 @default.
• W2256029097 hasVolume "28" @default.
• W2256029097 isParatext "false" @default.
• W2256029097 isRetracted "false" @default.
• W2256029097 magId "2256029097" @default.
• W2256029097 workType "article" @default.